A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Inclusion Criteria:

- In good health. Any underlying chronic illness must be documented to be in stable
condition.

- A female participant is eligible to participate if she is not pregnant, not
breastfeeding, and at least 1 of the following conditions applies: a) not a woman of
childbearing potential (WOCBP) OR b) a WOCBP who agrees to use 1 of the contraceptive
methods as defined in the protocol during the treatment period and for at least 6
weeks after the last dose of study intervention.

Exclusion Criteria:

- History of invasive pneumococcal disease (IPD, positive blood culture, positive
cerebrospinal fluid culture, or positive culture at another sterile site) or known
history of other culture-positive pneumococcal disease within 3 years before Visit 1
(Day 1)

- Known hypersensitivity to any component of pneumococcal polysaccharide vaccine,
pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine

- Known hypersensitivity to any component of influenza vaccines, including egg protein,
or following a previous dose of any influenza vaccine

- Known or suspected impairment of immunological function

- Experienced Guillain-Barré syndrome within 6 weeks of receiving a previous influenza
vaccination

- Coagulation disorder contraindicating intramuscular vaccinations.

- History of malignancy ≤5 years prior to signing informed consent, except for
adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

- A WOCBP who has a positive urine or serum pregnancy test before the first vaccination
at Visit 1 (Day 1)

- Prior administration of any PCV (e.g., Prevnar 13™) or is expected to receive any
pneumococcal vaccine during the study outside of the protocol

- Prior administration of PNEUMOVAX™23 ≤12 months before Visit 1 (Note: individuals who
received PNEUMOVAX™23 >12 months prior to Visit 1 are eligible for this study)

- Previous receipt of influenza vaccine during the 2018/2019 flu season or expected to
receive any influenza vaccine during the study outside of the protocol

- Received systemic corticosteroids (≥20 mg/day prednisone equivalent) for ≥14
consecutive days and has not completed intervention at least 30 days before study
entry

- Received systemic corticosteroids exceeding physiologic replacement doses
(approximately 5 mg/day prednisone equivalent) within 14 days before vaccination
(Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon
steroid injections], and inhaled/nebulized steroids are permitted)

- Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat
cancer or other conditions, and interventions associated with organ or bone marrow
transplantation, or autoimmune disease

- Received a blood transfusion or blood products, including immunoglobulin within the 6
months before receipt of study vaccine or is scheduled to receive a blood transfusion
or blood product within 30 days of receipt of study vaccine. Autologous blood
transfusions are not considered an exclusion criterion.

- Is currently participating in or has participated in an interventional clinical study
with an investigational compound or device within 2 months of participating in this
current study

- Is a user of recreational or illicit drugs or has had a recent history (within the
last year) of drug or alcohol abuse or dependence as assessed by the study
investigator

- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or
child) who is investigational site or Sponsor staff directly involved with this study.